EMBC (Embecta) Risk Assessment


EMBC Embecta Corp EMBC
53 GF Score
Price $3.20
GF Value $12.68
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Embecta Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Embecta is: High Risk: Sensitive to economic or industry trends.

Embecta  (NAS:EMBC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Embecta Risk Assessment Related Terms

EMBC vs KRMD, SMTI, PDEX: Risk Assessment Comparison

For the Medical Instruments & Supplies subindustry, Embecta's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Embecta Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Embecta's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Embecta's Risk Assessment falls into.


EMBC
53GF Score
Embecta Corp EMBC
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Embecta (EMBC) Overvalued in 2026?

Based on GuruFocus' analysis, Embecta stock appears to be undervalued. The current stock price of $3.20 is trading 74.8% below its estimated GF Value™ of $12.68. GuruFocus considers Embecta to be Possible Value Trap.

Key valuation signals for EMBC:

  • Risk Assessment:
  • GF Value™: $12.68 vs. price of $3.20 (74.8% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the EMBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Embecta Business Description

Other Exchanges JX7:Germany
Address 300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
53GF Score

Get the complete analysis for EMBC

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.20
Price
$12.68
GF Value